You are here

momelotinib

Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks

Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks

BioSpace

Gilead Sciences

Flag link:

GSK explores new avenues for JAK drug in $1.9B Sierra buy amid pending FDA decision

GSK explores new avenues for JAK drug in $1.9B Sierra buy amid pending FDA decision

Fierce Biotech

Sierra Oncology

Flag link:

Was This Acquisition a Smart Move for GlaxoSmithKline?

Was This Acquisition a Smart Move for GlaxoSmithKline?

Motley Fool

Sierra Oncology

bone marrow cancer

Flag link:

Sierra doubles down on ex-Gilead drug, deprioritizes other assets

Sierra doubles down on ex-Gilead drug, deprioritizes other assets

Fierce Biotech

Sierra Oncology

Gilead Sciences

Flag link:

Sierra Oncology Acquires Gilead’s Stalled Myelofibrosis Drug

Sierra Oncology Acquires Gilead’s Stalled Myelofibrosis Drug

Xconomy

Gilead Sciences

Sierrra Oncology

Flag link:

Gilead Fails to Beat Incyte’s Jakafi Drug

Gilead Fails to Beat Incyte’s Jakafi Drug

Investopedia

Gilead Sciences

Flag link: